 |
| Logo taken from Business Wire |
It
said its dedication can help prevent diseases and save lives, in a statement on
this week.
“In
support of this commitment, and to help address the practical constraints
experienced by health workers operating in many Gavi countries, Pfizer [has] developed
Prevenar 13® in the Multi-Dose Vial-MDV presentation (4 doses per vial),” the
company announced.
“This
new presentation will help to significantly reduce storage requirements and
shipping costs in communities with health systems that are still developing.”
The
company said the MDV presentation received a positive opinion from the
Committee for Medicinal Products for Human Use (CHMP) of the European Medicines
Agency (EMA) in April 2016.
Subsequently
the MDV was pre-qualified by the WHO in July 2016, it added.
In
January this year, Pfizer launched the new multi-dose vial- MDV which was
prequalified in accordance with WHO’s ‘open container policy.’
It
said the which has ‘open container’ attributes, allows for the fourth dose to
be used for up to 28 days after the first dose in drawn and providing the
recommended cold storage requirements have been met.
To
ensure the efficient use of the multi-dose vial, Pfizer is supporting Gavi
countries with a refresher training of trainers programme on a variety of
immunization topics including the proper handling of multi dose vials with open
container policy.
Pfizer
partnered with AMP Services, an organization dedicated to providing the tools
to promote preventive medicine and public health worldwide, to execute the
training of trainers sessions in 16 countries in 2017.
During
the first four months of launch, fifteen countries have received the new MDV
and nine of these have completed the training of trainers programme. These
training sessions were well received by the national and regional trainers.
“We
developed training materials that are easy to use for health workers and allow
for interactive learning process at all levels”, Georgiana Golodnius, Training
Project Manager of AMP Services said.
“In
the countries where we have implemented training of the trainers, 97.3% of the
participants think the developed training tools are useful and relevant.”
Mr.
Mwagomba, trainer in Malawi said: “Indeed we learnt a lot from the training and
I feel the knowledge gained will be used to train other health workers in the
country.”
Pfizer
said it is committed to constant innovation and development to ensure that the
challenges many face throughout the world- geographical, economical and
operational- can and will be met.
By TNBES
Follow on Facebook: The North Bank Evening Standard
No comments:
Post a Comment
The views expressed in this section are the authors' own. It does not represent The North Bank Evening Standard (TNBES)'s editorial policy. Also, TNBES is not responsible for content on external links.